Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV‐infected patients: A double‐blind placebo‐controlled study
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the efficacy and tolerance of fluconazole (150 mg oral dose, once a week) in the prevention of recurrent oropharyngeal candidiasis in patients with moderate to severe human immunodeficiency virus (HIV) infection. DESIGN: A randomised, double-blind, placebo-controlled trial. PATIENTS: Eighty-four patients with moderate to severe HIV infection who had successfully completed two to four weeks treatment with fluconazole for oropharyngeal candidiasis were randomly allocated to receive either placebo or fluconazole. Pre-treatment clinical and laboratory characteristics were similar in the two groups. OUTCOME MEASURES: Success was classified as absence throughout the course of treatment of clinical evidence of oropharyngeal candidiasis, and failure as recurrence or relapse of symptomatic oropharyngeal candidiasis. RESULTS: Of 73 evaluable patients the median time to relapse was > or = 168 days in the fluconazole group and 37 days in the placebo group (P < 0.0001). One patient in the placebo group and 18 patients in the fluconazole group completed six months' treatment without clinical relapse (P < 0.001). CONCLUSION: Fluconazole was well tolerated and prevented clinical relapse of oropharyngeal candidiasis in 71% of patients who completed three months of treatment (95% confidence interval [CI], 55-86) and 58% (95% CI, 41-75) who completed six months of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grant, S. M., & Clissold, S. P. (1990) · Drugs · doi:10.2165/00003495-199039060-00006 · Cited by 661
COMPARISON OF FLUCONAZOLE AND KETOCONAZOLE FOR OROPHARYNGEAL CANDIDIASIS IN AIDS
De Wit, S., Goossens, H., Weerts, D., & Clumeck, N. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92572-5 · Cited by 199
Cited by
Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?
Charlier, C., Hart, E., Lefort, A., Ribaud, P., Dromer, F., Denning, D. W., & Lortholary, O. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki473 · Cited by 184
Prophylaxis with Weekly Versus Daily Fluconazole for Fungal Infections in Patients with AIDS
Havlir, D. V., Dubé, M. P., McCutchan, J. A., Forthal, D. N., Kemper, C. A., Dunne, M. W., Parenti, D. M., Kumar, P. N., White, A. C., Witt, M. D., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/515018 · Cited by 72
Revankar, S. G., Kirkpatrick, W. R., McAtee, R. K., Dib, O. P., Fothergill, A. W., Redding, S. W., Rinaldi, M. G., Hilsenbeck, S. G., & Patterson, T. F. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00137-5 · Cited by 67
Vazquez, J. A., Peng, G., Sobel, J. D., Steele‐Moore, L., Schuman, P., Holloway, W., Neaton, J. D., & (CPCRA), T. T. B. C. P. F. C. R. O. A. (2001) · Clinical Infectious Diseases · doi:10.1086/322641 · Cited by 57
“In addition, either daily or intermittent doses of fluconazole have been shown to be effective in preventing mucosal candidiasis in patients with AIDS [12-17].”
BackgroundVazquez, J. A., Sobel, J. D., Peng, G., Steele‐Moore, L., Schuman, P., Holloway, W., Neaton, J. D., & (CPCRA), T. T. B. C. P. F. C. R. I. A. (1999) · Clinical Infectious Diseases · doi:10.1086/514746 · Cited by 51
“In addition, daily or intermittent doses of fluconazole have been shown to be effective in preventing mucosal candidiasis in AIDS patients [8-13].”
Background
Metadata
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV‐infected patients: A double‐blind placebo‐controlled study. https://app.cochat.ai/papers/10.5694/j.1326-5377.1993.tb121784.x
- The paper
- Marriott, D. J. E., Harkness, J. L., Jones, P. D., Hoy, J. F., & Speed, B. R. (1993). Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV‐infected patients: A double‐blind placebo‐controlled study. Medical Journal of Australia. https://doi.org/10.5694/j.1326-5377.1993.tb121784.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.